Nexell Cuts Deals With French Company
- Share via
Nexell Therapeutics Inc., an Irvine supplier of therapeutic and diagnostic products based on stem cell technology, said Wednesday that it has entered into two worldwide licensing agreements with a French company.
The agreements with Diaclone, SA, in Besancon, France, gives Nexell access to a suite of seven monoclonal antibodies for use in ex vivo cell therapy.
Terms of the agreements were not disclosed.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
